Hello Friends! Are you looking to invest in the stock market, or have you already invested? Would you like to know the predictions regarding the potential fluctuations in your shares? If so, you have landed on exactly the right page. On this page, you will find information regarding Sai Parenterals IPO GMP, Sai Parenterals owner, Sai parenterals share price future, Sai Parenterals IPO price, Sai parenterals share price history, and much more. Furthermore, this page provides details on Sai Parenterals‘s share price targets 2026, 2027, 2028, 2029, 2030, 2040, and beyond.
Sai Parenterals Company Information
| Number of employees | 298 (2025) |
| Headquarters | India |
| Founded | 1988 |
| Subsidiary | SP Analytics Private Limited |
Sai Parenterals Share Price Target Overview
- Current Price – 490.00
- Open – 504.85
- High – 505.10
- Low – 487.80
- Mkt cap – 2.16KCr
- P/E ratio – N/A
- 52-wk high – 526.30
- 52-wk low – 400.00
- Dividend – N/A
- Qtrly div amt – N/A
Sai Parenterals Share Price Chart
Sai Parenterals Share Price Target Tomorrow
| Sai Parenterals Share Price Target Years | Sai Parenterals Share Price Target |
| 2026 | ₹530 |
| 2027 | ₹600 |
| 2028 | ₹690 |
| 2029 | ₹780 |
| 2030 | ₹870 |
Sai Parenterals Share Price Target 2026
The target for Sai Parenterals’s share price in 2026 is projected to range between ₹520 and ₹530. As of the start of May 2026, Sai Parenterals’s share price stood at ₹490.00. Compared to the previous year, Sai Parenterals’s share price has witnessed an increase this year.
Sai Parenterals Share Price Target 2027
The target for Sai Parenterals’s share price in 2027 is projected to range between ₹590 and ₹600. On 8 May 2026, Sai Parenterals Share price NSE is 490.00 INR. Compared to last year, no significant difference has been observed in the share price of Sai Parenterals. The share price has increased by approximately 80-90 rupees.
Sai Parenterals Share Price Target 2030
The target for Sai Parenterals’s share price in 2030 is projected to range between ₹860 and ₹870. Over the past several years, the company has generated substantial profits, and investors, too, have earned handsome returns proportionate to their shareholdings. We remain optimistic that the company will continue to generate profits in the future, thereby ensuring continued returns for its investors.
Risks and Challenges Of Sai Parenterals Share Price
Here are 8 key factors affecting the growth of Sai Parenterals share price:
- Sai Parenterals operates in the pharmaceutical sector, where strict regulatory approvals and compliance requirements can create operational challenges and affect business growth.
- Any warning letters, product recalls, or quality control issues from regulatory authorities can damage the company’s reputation and negatively impact the share price.
- Rising raw material and API (Active Pharmaceutical Ingredient) costs can increase manufacturing expenses and reduce profit margins.
- The company faces intense competition from large pharmaceutical companies and generic drug manufacturers, which can put pressure on pricing and market share.
- Dependence on a limited product portfolio or specific therapeutic segments may increase business risk if demand weakens in those categories.
- Delays in product approvals, manufacturing expansion, or new launches can slow revenue growth and affect investor confidence.
- Currency fluctuations and global economic uncertainty may impact export earnings and international business performance.
- Low liquidity and volatility often seen in small-cap pharmaceutical stocks can lead to sharp movements in Sai Parenterals share price during market fluctuations.
Read Also:- Firstsource Solutions Share Price Target Tomorrow From 2026 to 2030 – Current Chart, Market Overview
Key Factors Affecting Growth Sai Parenterals Share Price
Here are 8 key factors affecting the growth of Sai Parenterals share price:
- Growing demand for pharmaceutical and healthcare products can support higher sales growth for Sai Parenterals and positively impact its share price.
- Expansion of manufacturing capacity and production facilities can help the company increase output and meet rising market demand.
- New product launches and diversification into different therapeutic segments can strengthen revenue sources and reduce business dependency on limited products.
- Strong regulatory approvals and compliance with quality standards can improve market credibility and support export opportunities.
- Growth in domestic healthcare spending and rising awareness about medical treatments can increase demand for the company’s pharmaceutical products.
- Export expansion into international markets can help Sai Parenterals improve revenue diversification and long-term business growth.
- Better operational efficiency, cost management, and improved profit margins can increase investor confidence and support stock performance.
- Consistent financial growth, stronger quarterly earnings, and positive market sentiment toward the pharmaceutical sector can drive long-term growth in Sai Parenterals share price.
Sai Parenterals Shareholding Pattern
| Promoter | 51.2% |
| FII | 5.7% |
| DII | 12.9% |
| Public | 30.2% |
Income Statement Of Sai Parenterals
|
All values in INR
|
Jun 2025
|
Sep 2025
|
|---|---|---|
|
Revenue
|
434.59M
|
434.59M
|
|
Cost of goods sold
|
285.99M
|
285.99M
|
|
Cost of revenue
|
285.99M
|
285.99M
|
|
Research and development expenses
|
–
|
–
|
|
Total research and development expenses
|
–
|
–
|
|
Selling, general, and admin expenses
|
35.61M
|
35.61M
|
|
Operating expense
|
78.81M
|
78.81M
|
|
Total operating expenses
|
364.80M
|
364.80M
|
|
Operating income
|
69.80M
|
69.80M
|
|
Other non operating income
|
9.60M
|
9.60M
|
|
EBT including unusual items
|
55.79M
|
55.79M
|
|
EBT excluding unusual items
|
55.79M
|
55.79M
|
|
Income tax expense
|
16.97M
|
16.97M
|
|
Effective tax rate
|
30.42%
|
30.42%
|
|
Other operating expenses
|
28.78M
|
28.78M
|
|
Net income
|
38.82M
|
38.82M
|
|
Net profit margin
|
8.93%
|
8.93%
|
|
Earnings per share
|
–
|
–
|
|
Interest and investment income
|
580.00K
|
580.00K
|
|
Interest expense
|
-20.79M
|
-20.79M
|
|
Net interest expenses
|
-20.21M
|
-20.21M
|
|
Depreciation and amortization charges
|
14.43M
|
14.43M
|
|
EBITDA
|
83.51M
|
83.51M
|
|
Gain or loss from assets sale
|
–
|
–
|
Hi, I’m Ronak, a news writer covering the latest updates in automobiles, education, smartphones, and trending topics. I focus on delivering simple, clear, and timely news to keep readers informed about what’s happening around the world.